EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study

Norma P Tavakoli iD, Dorota Gruber iD, Niki Armstrong, Wendy K Chung iD, Breanne Maloney, Sunju Park, Julia Wynn, Carrie Koval-Burt, Lorraine Verdade, David H Tegay, Lilian L Cohen, Natasha Shapiro und 12 weitere

Annals of Clinical and Translational Neurology · 2023-08 · 10 (8) · 1383-1396

DOI: 10.1002/acn3.51829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 23.06.2023. Verfasst von Norma P Tavakoli und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, New York, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parent Project Muscular Dystrophy, PerkinElmer, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Duchenne muscular dystrophy (DMD) is an X‐linked disorder resulting in progressive muscle weakness and atrophy, cardiomyopathy, and in late stages, cardiorespiratory impairment, and death. As treatments for DMD have expanded, a DMD newborn screening (NBS) pilot study was conducted in New York State to evaluate the feasibility and benefit of NBS for DMD and to provide an early pre‐symptomatic diagnosis.

Methods

At participating hospitals, newborns were recruited to the pilot study, and consent was obtained to screen the newborn for DMD. The first‐tier screen measured creatine kinase‐MM (CK‐MM) in dried blood spot specimens submitted for routine NBS. Newborns with elevated CK‐MM were referred for genetic counseling and genetic testing. The latter included deletion/duplication analysis and next‐generation sequencing (NGS) of the DMD gene followed by NGS for a panel of neuromuscular conditions if no pathogenic variants were detected in the DMD gene.

Results

In the two‐year pilot study, 36,781 newborns were screened with CK‐MM. Forty‐two newborns (25 male and 17 female) were screen positive and referred for genetic testing. Deletions or duplications in the DMD gene were detected in four male infants consistent with DMD or Becker muscular dystrophy. One female DMD carrier was identified.

Interpretation

This study demonstrated that the state NBS program infrastructure and screening technologies we used are feasible to perform NBS for DMD. With an increasing number of treatment options, the clinical utility of early identification for affected newborns and their families lends support for NBS for this severe disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneInfantHumansMaleInfant, NewbornFemaleNeonatal ScreeningPilot ProjectsGenetic TestingHigh-Throughput Nucleotide Sequencing

Autor:innen und Institutionen

  • Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Department of Biomedical Sciences, State University of New York, Albany, New York, USA.
  • Department of Pediatrics, Cohen Children's Medical Center, Northwell Health, New Hyde Park, New York, USA.
  • Departments of Pediatrics and Cardiology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Parent Project Muscular Dystrophy, Washington, DC, USA.
  • Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Norma P Tavakoli, Dorota Gruber, Wendy K Chung

Förderung

  • Parent Project Muscular Dystrophy
  • PerkinElmer
  • Pfizer
  • PTC Therapeutics
  • Sarepta Therapeutics

Zitieren

APA

Tavakoli, N. P., Gruber, D., Armstrong, N., Chung, W. K., Maloney, B., Park, S., Wynn, J., Koval-Burt, C., Verdade, L., Tegay, D. H., Cohen, L. L., Shapiro, N., Kennedy, A., Noritz, G., Ciafaloni, E., Weinberger, B., Ellington, M., Schleien, C., Spinazzola, R., …, & Duchenne Muscular Dystrophy Pilot Study Group (2023). Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study. Annals of Clinical and Translational Neurology, 10(8), 1383-1396. https://doi.org/10.1002/acn3.51829

Vancouver

Tavakoli NP, Gruber D, Armstrong N, Chung WK, Maloney B, Park S, et al. Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study. Annals of Clinical and Translational Neurology. 2023;10(8):1383-1396. doi:10.1002/acn3.51829

BibTeX
@article{Tavakoli2023,
  author = {Tavakoli, Norma P and Gruber, Dorota and Armstrong, Niki and Chung, Wendy K and Maloney, Breanne and Park, Sunju and Wynn, Julia and Koval-Burt, Carrie and Verdade, Lorraine and Tegay, David H and Cohen, Lilian L and Shapiro, Natasha and Kennedy, Annie and Noritz, Garey and Ciafaloni, Emma and Weinberger, Barry and Ellington, Marty and Schleien, Charles and Spinazzola, Regina and Sood, Sunil and Brower, Amy and Lloyd-Puryear, Michele and Caggana, Michele and Duchenne Muscular Dystrophy Pilot Study Group, Duchenne Muscular Dystrophy Pilot Study Group},
  title = {Newborn screening for Duchenne muscular dystrophy: A two‐year pilot study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2023},
  volume = {10},
  number = {8},
  pages = {1383--1396},
  doi = {10.1002/acn3.51829}
}
Kostenlos starten →